Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 10/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 6/20 | 0.43 |
| ▸ | KIT | P10721 | 5/20 | 0.43 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12235598 | 0.85 | ULK1 (0.60) | PTK2PTK2BKCNH2ULK1FLT3 | |
| SCHEMBL15328911 | 0.85 | ULK1 (0.60) | PTK2PTK2BKCNH2ULK1FLT3 | |
| SCHEMBL14616066 | 0.85 | ULK1 (0.60) | PTK2PTK2BKCNH2ULK1FLT3 | |
| SCHEMBL3572092 | 0.83 | FGFR1 (0.59) | PTK2PTK2BKCNH2ULK1SYK | |
| SCHEMBL13313544 | 0.83 | SYK (0.49) | PTK2PTK2BKCNH2ULK1SYK | |
| SCHEMBL5576857 | 0.83 | ULK1 (0.56) | PTK2PTK2BKCNH2ULK1FLT3 | |
| SCHEMBL3566464 | 0.83 | PTK2 (0.55) | PTK2PTK2BKCNH2ULK1FLT3 | |
| SCHEMBL2526061 | 0.83 | PTK2 (0.57) | PTK2PTK2BKCNH2ULK1FLT3 | |
| SCHEMBL5575713 | 0.83 | KIT (0.62) | PTK2PTK2BKCNH2ULK1SYK | |
| SCHEMBL5575711 | 0.83 | KIT (0.62) | PTK2PTK2BKCNH2ULK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | PTK2 1486/4885PTK2B 2938/4885KCNH2 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.